FDA Com­mis­sion­er Robert Califf high­lights need for ‘cre­ative ap­proach­es’ for rare dis­ease ther­a­pies

The FDA’s top of­fi­cials con­tin­ue to call for new ways to reg­u­late up-and-com­ing med­i­cines for rare and ul­tra-rare dis­eases.

“We’re about to see a tsuna­mi of ther­a­pies for a rare and ul­tra rare dis­ease, and I don’t think any of us think the cur­rent path­ways are op­ti­mal,” FDA com­mis­sion­er Robert Califf said dur­ing a Q&A at the Com­pas­sion­ate Use and Preap­proval Ac­cess con­fer­ence host­ed by New York Uni­ver­si­ty on Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER